Olema Pharmaceuticals Statistics
Total Valuation
OLMA has a market cap or net worth of $942.35 million. The enterprise value is $484.94 million.
| Market Cap | 942.35M |
| Enterprise Value | 484.94M |
Important Dates
The last earnings date was Monday, August 10, 2026, after market close.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OLMA has 87.50 million shares outstanding. The number of shares has increased by 30.72% in one year.
| Current Share Class | 87.50M |
| Shares Outstanding | 87.50M |
| Shares Change (YoY) | +30.72% |
| Shares Change (QoQ) | +1.61% |
| Owned by Insiders (%) | 2.68% |
| Owned by Institutions (%) | 88.50% |
| Float | 59.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.19 |
| P/TBV Ratio | 2.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.86, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.86 |
| Quick Ratio | 8.76 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -52.74% and return on invested capital (ROIC) is -35.25%.
| Return on Equity (ROE) | -52.74% |
| Return on Assets (ROA) | -31.82% |
| Return on Invested Capital (ROIC) | -35.25% |
| Return on Capital Employed (ROCE) | -51.00% |
| Weighted Average Cost of Capital (WACC) | 15.24% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.36M |
| Employee Count | 150 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +95.46% in the last 52 weeks. The beta is 2.01, so OLMA's price volatility has been higher than the market average.
| Beta (5Y) | 2.01 |
| 52-Week Price Change | +95.46% |
| 50-Day Moving Average | 11.22 |
| 200-Day Moving Average | 17.58 |
| Relative Strength Index (RSI) | 42.55 |
| Average Volume (20 Days) | 967,378 |
Short Selling Information
The latest short interest is 15.96 million, so 18.24% of the outstanding shares have been sold short.
| Short Interest | 15.96M |
| Short Previous Month | 15.10M |
| Short % of Shares Out | 18.24% |
| Short % of Float | 26.95% |
| Short Ratio (days to cover) | 13.77 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -221.13M |
| Pretax Income | -204.57M |
| Net Income | -204.57M |
| EBITDA | -220.68M |
| EBIT | -221.13M |
| Earnings Per Share (EPS) | -$2.13 |
Balance Sheet
The company has $461.07 million in cash and $3.66 million in debt, with a net cash position of $457.41 million or $5.23 per share.
| Cash & Cash Equivalents | 461.07M |
| Total Debt | 3.66M |
| Net Cash | 457.41M |
| Net Cash Per Share | $5.23 |
| Equity (Book Value) | 430.56M |
| Book Value Per Share | 4.92 |
| Working Capital | 416.86M |
Cash Flow
In the last 12 months, operating cash flow was -$164.74 million and capital expenditures -$221,000, giving a free cash flow of -$164.96 million.
| Operating Cash Flow | -164.74M |
| Capital Expenditures | -221,000 |
| Depreciation & Amortization | 451,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -164.96M |
| FCF Per Share | -$1.89 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OLMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.72% |
| Shareholder Yield | -30.72% |
| Earnings Yield | -21.71% |
| FCF Yield | -17.50% |
Analyst Forecast
The average price target for OLMA is $39.30, which is 264.90% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $39.30 |
| Price Target Difference | 264.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |